Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note released on Wednesday morning,Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q1 2026 earnings at ($1.17) EPS, Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.79) EPS and FY2026 earnings at ($3.64) EPS.

Several other brokerages have also recently issued reports on KPTI. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a research report on Wednesday, December 17th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Royal Bank Of Canada reduced their target price on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, November 4th. Cantor Fitzgerald started coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Karyopharm Therapeutics Stock Performance

Shares of KPTI stock opened at $9.67 on Wednesday. Karyopharm Therapeutics has a 12-month low of $3.51 and a 12-month high of $10.38. The stock has a market capitalization of $177.35 million, a P/E ratio of -0.58 and a beta of 0.21. The firm’s 50 day moving average is $7.26 and its 200 day moving average is $6.42.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The company had revenue of $34.08 million for the quarter, compared to analysts’ expectations of $33.16 million. As a group, equities analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Baird Financial Group Inc. bought a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $45,000. XTX Topco Ltd purchased a new position in shares of Karyopharm Therapeutics in the second quarter valued at $56,000. Corient Private Wealth LLC purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at $74,000. Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics in the fourth quarter worth $95,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Karyopharm Therapeutics during the fourth quarter valued at $135,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics News Roundup

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: HC Wainwright raised Q1–Q4 2026 and FY2026 EPS forecasts (e.g., FY26 from ($5.25) to ($3.64)) and reiterated a “Buy” rating with a $15 price target — a clear analyst positive that can support upside versus the current sub‑$15 market price. Article Title
• Neutral Sentiment: Short interest entries show zero shares reported and a 0.0 days‑to‑cover ratio (with NaN increases noted) — the data appears anomalous and unlikely to be a meaningful driver until corrected/clarified by exchanges or reporting firms.
• Negative Sentiment: Shareholders approved a major increase in authorized shares — this creates a risk of future dilution (issuances for financing, partnerships or M&A), which typically weighs on share price unless proceeds fund clear value‑creating initiatives. Article Title

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.